Source:http://linkedlifedata.com/resource/pubmed/id/16507416
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2006-3-1
|
| pubmed:abstractText |
The role of primary systemic therapy (PST) in the treatment of operable breast cancer is currently under intensive investigation in the hope of allowing greater conservation of the breast, and emerging evidence suggests that induction of a pathological complete response (pCR) is at least, to some extent, predictive of long-term clinical response. In this review, we highlight the issues of pathologic evaluation after PST.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0753-3322
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
59 Suppl 2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
S387-92
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading | |
| pubmed:year |
2005
|
| pubmed:articleTitle |
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer.
|
| pubmed:affiliation |
c/o Komagome Hospital, Honkomagome, Bunkyo-ku, Tokyo, Japan. kurochan@dd/iij4u.or.jp
|
| pubmed:publicationType |
Journal Article,
Review,
Meta-Analysis
|